REFERENCES

1. Rawla P. Epidemiology of prostate cancer. World J Oncol. 2019;10:63-89.

2. Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12-49.

3. Bubendorf L, Schöpfer A, Wagner U, et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol. 2000;31:578-83.

4. Sandhu S, Moore CM, Chiong E, et al. Prostate cancer. Lancet. 2021;398:1075-90.

5. Pippione AC, Boschi D, Pors K, Oliaro-bosso S, Lolli ML. Androgen-AR axis in primary and metastatic prostate cancer: chasing steroidogenic enzymes for therapeutic intervention. J Cancer Metastasis Treat. 2017;3:328.

6. Blatt EB, Raj GV. Molecular mechanisms of enzalutamide resistance in prostate cancer. Cancer Drug Resist. 2019;2:189-97.

7. Sekino Y, Teishima J. Molecular mechanisms of docetaxel resistance in prostate cancer. Cancer Drug Resist. 2020;3:676-85.

8. Warburg O, Negelein E, Posener K. Versuche an überlebendem carcinomgewebe. Klin Wochenschr. 1924;3:1062-4.

9. Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol. 1927;8:519-30.

10. Pfeiffer T, Schuster S, Bonhoeffer S. Cooperation and competition in the evolution of ATP-producing pathways. Science. 2001;292:504-7.

11. Pliszka M, Szablewski L. Glucose transporters as a target for anticancer therapy. Cancers. 2021;13:4184.

12. Pragallapati S, Manyam R. Glucose transporter 1 in health and disease. J Oral Maxillofac Pathol. 2019;23:443-9.

13. Younes M, Lechago LV, Somoano JR, Mosharaf M, Lechago J. Wide expression of the human erythrocyte glucose transporter Glut1 in human cancers. Cancer Res. 1996;56:1164-7. Available from: https://aacrjournals.org/cancerres/article/56/5/1164/503027/Wide.

14. Szablewski L. Glucose transporters as markers of diagnosis and prognosis in cancer diseases. Oncol Rev. 2022;16:561.

15. Wang T, Wang J, Hu X, Huang XJ, Chen GX. Current understanding of glucose transporter 4 expression and functional mechanisms. World J Biol Chem. 2020;11:76-98.

16. Macheda ML, Rogers S, Best JD. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol. 2005;202:654-62.

17. Zheng J. Energy metabolism of cancer: glycolysis versus oxidative phosphorylation (Review). Oncol Lett. 2012;4:1151-7.

18. Chen CL, Lin CY, Kung HJ. Targeting mitochondrial OXPHOS and their regulatory signals in prostate cancers. Int J Mol Sci. 2021;22:13435.

19. Butler LM, Centenera MM, Swinnen JV. Androgen control of lipid metabolism in prostate cancer: novel insights and future applications. Endocr Relat Cancer. 2016;23:R219-27.

20. Effert P, Beniers AJ, Tamimi Y, Handt S, Jakse G. Expression of glucose transporter 1 (Glut-1) in cell lines and clinical specimens from human prostate adenocarcinoma. Anticancer Res. 2004;24:3057-63. Available from: https://ar.iiarjournals.org/content/24/5A/3057/tab. [Last accessed on 24 Jan 2025]

21. Oyama N, Akino H, Suzuki Y, et al. Prognostic value of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography imaging for patients with prostate cancer. Mol Imaging Biol. 2002;4:99-104.

22. Parmar K, Mauch P, Vergilio JA, Sackstein R, Down JD. Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia. Proc Natl Acad Sci U S A. 2007;104:5431-6.

23. Diedrich JD, Rajagurubandara E, Herroon MK, Mahapatra G, Hüttemann M, Podgorski I. Bone marrow adipocytes promote the Warburg phenotype in metastatic prostate tumors via HIF-1α activation. Oncotarget. 2016;7:64854-77.

24. Spencer JA, Ferraro F, Roussakis E, et al. Direct measurement of local oxygen concentration in the bone marrow of live animals. Nature. 2014;508:269-73.

25. Vaupel P, Höckel M, Mayer A. Detection and characterization of tumor hypoxia using pO₂ histography. Antioxid Redox Signal. 2007;9:1221-35.

26. Zhang Y, Li Q, Huang Z, et al. Targeting glucose metabolism enzymes in cancer treatment: current and emerging strategies. Cancers. 2022;14:4568.

27. Temre MK, Kumar A, Singh SM. An appraisal of the current status of inhibition of glucose transporters as an emerging antineoplastic approach: promising potential of new pan-GLUT inhibitors. Front Pharmacol. 2022;13:1035510.

28. Chen X, Bergmeier SC. Compositions and methods for glucose transport inhibition. US11072576B2, 2021. Available from: https://patents.google.com/patent/US11072576B2/en. [Last accessed on 10 Feb 2025].

29. Shriwas P, Roberts D, Li Y, et al. A small-molecule pan-class I glucose transporter inhibitor reduces cancer cell proliferation in vitro and tumor growth in vivo by targeting glucose-based metabolism. Cancer Metab. 2021;9:14.

30. Liu Y, Zhang W, Cao Y, Liu Y, Bergmeier S, Chen X. Small compound inhibitors of basal glucose transport inhibit cell proliferation and induce apoptosis in cancer cells via glucose-deprivation-like mechanisms. Cancer Lett. 2010;298:176-85.

31. Shi Q, Shen Q, Liu Y, et al. Increased glucose metabolism in TAMs fuels O-GlcNAcylation of lysosomal cathepsin B to promote cancer metastasis and chemoresistance. Cancer Cell. 2022;40:1207-1222.e10.

32. Jakobsson AW, Kundu S, Guo J, et al. Iron chelator VLX600 inhibits mitochondrial respiration and promotes sensitization of neuroblastoma cells in nutrition-restricted conditions. Cancers. 2022;14:3225.

33. Wang J, Xu W, Wang B, et al. GLUT1 is an AR target contributing to tumor growth and glycolysis in castration-resistant and enzalutamide-resistant prostate cancers. Cancer Lett. 2020;485:45-55.

34. LeRoy BE, Thudi NK, Nadella MV, et al. New bone formation and osteolysis by a metastatic, highly invasive canine prostate carcinoma xenograft. Prostate. 2006;66:1213-22.

35. Thudi NK, Shu ST, Martin CK, et al. Development of a brain metastatic canine prostate cancer cell line. Prostate. 2011;71:1251-63.

36. Simmons JK, Dirksen WP, Hildreth BE 3rd, et al. Canine prostate cancer cell line (probasco) produces osteoblastic metastases in vivo. Prostate. 2014;74:1251-65.

37. Elshafae SM, Dirksen WP, Alasonyalilar-Demirer A, et al. Canine prostatic cancer cell line (LuMa) with osteoblastic bone metastasis. Prostate. 2020;80:698-714.

38. Simmons JK, Hildreth III BE, Supsavhad W, et al. Animal models of bone metastasis. Vet Pathol. 2015;52:827-41.

39. Chlenski A, Nakashiro K, Ketels KV, Korovaitseva GI, Oyasu R. Androgen receptor expression in androgen-independent prostate cancer cell lines. Prostate. 2001;47:66-75.

40. Yun SJ, Kim SK, Kim J, et al. Transcriptomic features of primary prostate cancer and their prognostic relevance to castration-resistant prostate cancer. Oncotarget. 2017;8:114845-55.

41. Kumar A, Coleman I, Morrissey C, et al. Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer. Nat Med. 2016;22:369-78.

42. Thiemeyer H, Taher L, Schille JT, et al. An RNA-seq-based framework for characterizing canine prostate cancer and prioritizing clinically relevant biomarker candidate genes. Int J Mol Sci. 2021;22:11481.

43. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26:139-40.

44. Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43:e47.

45. Ye J, Coulouris G, Zaretskaya I, Cutcutache I, Rozen S, Madden TL. Primer-BLAST: a tool to design target-specific primers for polymerase chain reaction. BMC Bioinformatics. 2012;13:134.

46. Roberts DA, Wang L, Zhang W, et al. Isosteres of ester derived glucose uptake inhibitors. Bioorg Med Chem Lett. 2020;30:127406.

47. Haider M, Zhang X, Coleman I, et al. Epithelial mesenchymal-like transition occurs in a subset of cells in castration resistant prostate cancer bone metastases. Clin Exp Metastasis. 2016;33:239-48.

48. Suwabe Y, Nakano R, Namba S, et al. Involvement of GLUT1 and GLUT3 in the growth of canine melanoma cells. PLoS One. 2021;16:e0243859.

49. Liu Y, Cao Y, Zhang W, et al. A small-molecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo. Mol Cancer Ther. 2012;11:1672-82.

50. Chandler JD, Williams ED, Slavin JL, Best JD, Rogers S. Expression and localization of GLUT1 and GLUT12 in prostate carcinoma. Cancer. 2003;97:2035-42.

51. Reinicke K, Sotomayor P, Cisterna P, Delgado C, Nualart F, Godoy A. Cellular distribution of Glut-1 and Glut-5 in benign and malignant human prostate tissue. J Cell Biochem. 2012;113:553-62.

52. Mossa F, Robesti D, Sumankalai R, et al. Subtype and site specific-induced metabolic vulnerabilities in prostate cancer. Mol Cancer Res. 2023;21:51-61.

53. Whitburn J, Rao SR, Morris EV, et al. Metabolic profiling of prostate cancer in skeletal microenvironments identifies G6PD as a key mediator of growth and survival. Sci Adv. 2022;8:eabf9096.

54. Jiang H, Liu M, Deng Y, et al. Identification of prostate cancer bone metastasis related genes and potential therapy targets by bioinformatics and in vitro experiments. J Cell Mol Med. 2024;28:e18511.

55. Pienta KJ. Preclinical mechanisms of action of docetaxel and docetaxel combinations in prostate cancer. Semin Oncol. 2001;28:3-7.

56. Ippolito L, Marini A, Cavallini L, et al. Metabolic shift toward oxidative phosphorylation in docetaxel resistant prostate cancer cells. Oncotarget. 2016;7:61890-904.

57. Catanzaro D, Gabbia D, Cocetta V, et al. Silybin counteracts doxorubicin resistance by inhibiting GLUT1 expression. Fitoterapia. 2018;124:42-8.

58. Ginsberg HN, Zhang YL, Hernandez-Ono A. Regulation of plasma triglycerides in insulin resistance and diabetes. Arch Med Res. 2005;36:232-40.

59. Feingold KR. Lipid and lipoprotein metabolism. Endocrinol Metab Clin North Am. 2022;51:437-58.

60. Cameron S, Deblois G, Hawley JR, et al. Chronic hypoxia favours adoption to a castration-resistant cell state in prostate cancer. Oncogene. 2023;42:1693-703.